Activity of intrapleural recombinant gamma-interferon in malignant mesothelioma
1991; Wiley; Volume: 67; Issue: 8 Linguagem: Inglês
10.1002/1097-0142(19910415)67
ISSN1097-0142
AutoresC Boutin, J. R. Viallat, Nico van Zandwijk, Jean-Yves Douillard, Jacques Paillard, J C Guérin, Pierre Mignot, J Miguérès, François Varlet, Ayeda Jehan, E Delepoulle, M. Brandely,
Tópico(s)Medical Imaging and Pathology Studies
ResumoCancerVolume 67, Issue 8 p. 2033-2037 Clinical TrialFree Access Activity of intrapleural recombinant gamma-interferon in malignant mesothelioma C. Boutin MD, FCCP, Corresponding Author C. Boutin MD, FCCP Department of Pneumology, Medical School, MarseillesHǒpital de la Conception, 147, Bd. Baille, 13383 Marseille Cedex 5, France===Search for more papers by this authorJ. R. Viallat MD, J. R. Viallat MD Cancer Institute Paoli-Calmettes, MarseillesSearch for more papers by this authorN. van Zandwijk MD, N. van Zandwijk MD The Netherlands Cancer Institute Antoni Van Leenwenhoek Huis, Amsterdam, The NetherlandsSearch for more papers by this authorJ. T. Douillard MD, J. T. Douillard MD Centre René Gauducheau, NantesSearch for more papers by this authorJ. C. Paillard MD, J. C. Paillard MD Hopital Edouard Herriot, LyonSearch for more papers by this authorJ. C. Guerin MD, J. C. Guerin MD Hǒpital de la Croix Rousse, LyonSearch for more papers by this authorP. Mignot MD, P. Mignot MD Hǒpital Sabourin, Clermont-FerrandSearch for more papers by this authorJ. Migueres MD, J. Migueres MD Hǒpital Purpan, ToulouseSearch for more papers by this authorF. Varlet MD, F. Varlet MD Hǒpital de Bethune, BethuneSearch for more papers by this authorA. Jehan MD, A. Jehan MD CHU Cǒte de Nacre, CaenSearch for more papers by this authorE. Delepoulle MD, E. Delepoulle MD Hǒpital de Lens, LensSearch for more papers by this authorM. Brandely MD, M. Brandely MD Roussel Uclaf, Paris, FranceSearch for more papers by this author C. Boutin MD, FCCP, Corresponding Author C. Boutin MD, FCCP Department of Pneumology, Medical School, MarseillesHǒpital de la Conception, 147, Bd. Baille, 13383 Marseille Cedex 5, France===Search for more papers by this authorJ. R. Viallat MD, J. R. Viallat MD Cancer Institute Paoli-Calmettes, MarseillesSearch for more papers by this authorN. van Zandwijk MD, N. van Zandwijk MD The Netherlands Cancer Institute Antoni Van Leenwenhoek Huis, Amsterdam, The NetherlandsSearch for more papers by this authorJ. T. Douillard MD, J. T. Douillard MD Centre René Gauducheau, NantesSearch for more papers by this authorJ. C. Paillard MD, J. C. Paillard MD Hopital Edouard Herriot, LyonSearch for more papers by this authorJ. C. Guerin MD, J. C. Guerin MD Hǒpital de la Croix Rousse, LyonSearch for more papers by this authorP. Mignot MD, P. Mignot MD Hǒpital Sabourin, Clermont-FerrandSearch for more papers by this authorJ. Migueres MD, J. Migueres MD Hǒpital Purpan, ToulouseSearch for more papers by this authorF. Varlet MD, F. Varlet MD Hǒpital de Bethune, BethuneSearch for more papers by this authorA. Jehan MD, A. Jehan MD CHU Cǒte de Nacre, CaenSearch for more papers by this authorE. Delepoulle MD, E. Delepoulle MD Hǒpital de Lens, LensSearch for more papers by this authorM. Brandely MD, M. Brandely MD Roussel Uclaf, Paris, FranceSearch for more papers by this author First published: 15 April 1991 https://doi.org/10.1002/1097-0142(19910415)67:8 3.0.CO;2-8Citations: 90AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinkedInRedditWechat Abstract Twenty-two consecutive patients with malignant diffuse pleural mesothelioma were treated with recombinant gamma-interferon by the intrapleural route. Diagnosis was made by thoracoscopic examination and all cases were confirmed by the French Mesothelioma Panel of Pathologists. Patients were staged based on thoracoscopic examination and computed tomography (CT) scan: 12 patients were classified as Stage I and 10 were Stage II. A solution of gamma-interferon (40 × 106 U) was infused twice a week over 2 months. Every patient experienced fever. One patient had a Grade 2 leukopenia and one patient suffered from pleural empyema. Response evaluation was based on the following: (1) CT scan performed 2 weeks after treatment ended, and (2) repeat thoracoscopic examination with histopathologic verification in nine patients who had demonstrated a stabilization or a regression of the disease on CT scan. From the original group, 19 patients could be evaluated. Four complete thoracoscopic histopathologic responses and one partial response were observed in Stage I patients (56%). One partial response was observed in Stage II patients. References 1 McDonald AD, McDonald JC. Epidemiology of malignant mesothelioma. In: K Antman, J Aisner, eds. Asbestos Related Malignancy, vol. 1. Orlando, FL: Grune and Stratton, 1987; 31– 56. 2 Alberts A, Falkson G, Goedhals L, Vorobiof D, Van Der Merve C. Malignant pleural mesothelioma: A disease unaffected by current therapeutic manoeuvers. J Clin Oncol 1988; 6: 527– 535. 3 Schemin RJ. Surgical treatment of pleural mesothelioma. In: K Antman, J Aisner, eds. Asbestos Related Malignancy, vol. 1. Orlando, FL: Grune and Stratton, 1987; 232– 337. 4 Hillerdal G. Malignant mesothelioma 1982: Review of 4710 published cases. Br J Dis Chest 1983; 77: 321– 343. 5 Ruffie P, Feld R, Cormier Y et al. Diffuse malignant mesothelioma of the pleura in Ontario and Quebec: A retrospective study of 332 patients. J Clin Oncol 1989; 7: 1157– 1168. 6 Antman K, Shemin R, Ryan L et al. Malignant mesothelioma: Prognostic variables in a registry of 180 patients, the Dana-Farber Cancer Institute and Brigham and Women's Hospital experience over two decades, 1965–1985. J Clin Oncol 1988; 6: 147– 153. 7 Hand A, Husgafvel-Pursiainen K, Tammilchto L, Mattson K, Linnainmaa K. The effect of TNF combined with gamma interferon on human mesothelioma cell lines (Abstr). Proc Am Assoc Cancer Res 1989; 30: 437. 8 Manning LS, Bowman RV, Darby SB, Robinson BS. Lysis of human malignant mesothelioma cells by natural killer and lymphokine-activated killer cells. Am Rev Respir Dis 1989; 139: 1369– 1374. 9 Sklarin NT, Chahinian AP, Feuer E, Lahman LA, Szrajer L, Holland JF. Augmentation of activity of cis-diamminedichloroplatinum(II) and mitomycin C by interferon in human malignant mesothelioma xenografts in nude mice. Cancer Res 1988; 48: 64– 67. 10 Manuel D, Falk W. Interferon gamma is required in activation of macrophages for cytotoxicity. Cell Immunol 1983; 79: 396– 402. 11 Hammerstrom J. In vitro response to Corynebacterium parvum of human effusion lymphocytes isolated from patients with malignant and benign disease. Acta Pathol Microbiol Scand 1980; 88: 211– 218. 12 Butchart EG, Ashcroft T, Barnsley WC, Holden MP. Pleuropneumonectomy in the management of diffuse malignant mesothelioma of the pleura: Experience with 29 patients. Thorax 1976; 31: 15– 24. 13 Boutin C, Viallat JR, Rey F. Thoracoscopy in diagnosis, prognosis and treatment of mesothelioma. In: K Antman, J Aisner, eds. Asbestos Related Malignancy, vol. 1. Orlando, FL: Grune and Stratton, 1987; 301– 321. 14 Boutin C, Viallat JR, Cargnino P, Farisse P. Thoracoscopy in malignant pleural effusions. Am Rev Respir Dis 1981; 124: 588– 592. 15 Sridhar KS, Hussein AM, Feun LG, Zubrod CG. Activity of Pirarubicin (4′-O-Tetrahydropyranyladriamycin) in malignant mesothelioma. Cancer 1989; 63: 1084– 1091. 16 Zighelboim J, Nio Y, Berek JS, Bonavida B. Immunologic control of ovarian cancer. Nat Immun Cell Growth Regul 1988; 7: 216– 225. 17 Bereck JS, Hacker NF, Lichtenstein A et al. Intraperitoneal recombinant alpha-interferon for “salvage” immunotherapy in persistent epithelial ovarian cancer. Cancer Treat Rev 1985; (Suppl) 12: 23– 32. 18 Yasumoto K, Miyazaki K, Nagashima A et al. Induction of lymphokine-activated killer cells by intrapleural instillations of recombinant interleukin-2 in patients with malignant pleurisy due to lung cancer. Cancer Res 1987; 47: 2184– 2187. 19 Rosso R, Rimoldi R, Salvati F et al. Intrapleural natural beta interferon in the treatment of malignant pleural effusions. Oncology 1988; 45: 253– 256. 20 Fent K, Zbinden G. Toxicity of interferon and interleukin. Tips 1987; 8: 100– 105. 21 Rohatiner A, Balkwill F, Griffin D, Malpas J, Lister T. A phase I study of human lymphoblastoid interferon administered by continuous intravenous infusion. Cancer Chemother Pharmacol 1982; 9: 97– 102. Citing Literature Volume67, Issue815 April 1991Pages 2033-2037 ReferencesRelatedInformation
Referência(s)